🇺🇸 FDA
Pipeline program

OMP-18R5

18R5-001

Phase 1 mab completed

Quick answer

OMP-18R5 for Solid Tumors is a Phase 1 program (mab) at Mereo BioPharma Group plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Mereo BioPharma Group plc
Indication
Solid Tumors
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials